Literature DB >> 27831500

LPA Gene, Ethnicity, and Cardiovascular Events.

Sang-Rok Lee1, Anand Prasad1, Yun-Seok Choi1, Chao Xing1, Paul Clopton1, Joseph L Witztum1, Sotirios Tsimikas2.   

Abstract

BACKGROUND: The relationship of LPA single nucleotide polymorphisms (SNPs), apolipoprotein(a) isoforms, and lipoprotein(a) [Lp(a)] levels with major adverse cardiovascular events (MACE) in different ethnic groups is not well known.
METHODS: LPA SNPs, apolipoprotein(a) isoforms, Lp(a), and oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) levels were measured in 1792 black, 1030 white, and 597 Hispanic subjects enrolled in the Dallas Heart Study. Their interdependent relationships and prospective association with MACE after median 9.5-year follow-up were determined.
RESULTS: LPA SNP rs3798220 was most prevalent in Hispanics (42.38%), rs10455872 in whites (14.27%), and rs9457951 in blacks (32.92%). The correlation of each of these SNPs with the major apolipoprotein(a) isoform size was highly variable and in different directions among ethnic groups. In the entire cohort, Cox regression analysis with multivariable adjustment revealed that quartiles 4 of Lp(a) and OxPL-apoB were associated with hazard ratios (95% confidence interval) for time to MACE of 2.35 (1.50-3.69, P<0.001) and 1.89 (1.26-2.84, P=0.003), respectively, versus quartile 1. Addition of the major apolipoprotein(a) isoform and the 3 LPA SNPs to these models attenuated the risk, but significance was maintained for both Lp(a) and OxPL-apoB. Evaluating time to MACE in specific ethnic groups, Lp(a) was a positive predictor and the size of the major apolipoprotein(a) isoform was an inverse predictor in blacks, the size of the major apolipoprotein(a) isoform was an inverse predictor in whites, and OxPL-apoB was a positive predictor in Hispanics.
CONCLUSIONS: The prevalence and association of LPA SNPs with size of apolipoprotein(a) isoforms, Lp(a), and OxPL-apoB levels are highly variable and ethnicity-specific. The relationship to MACE is best explained by elevated plasma Lp(a) or OxPL-apoB levels, despite significant ethnic differences in LPA genetic markers.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  cardiovascular events; ethnicity; isoforms; lipoprotein(a); oxidized phospholipids; single nucleotide polymorphisms

Mesh:

Substances:

Year:  2016        PMID: 27831500      PMCID: PMC5241172          DOI: 10.1161/CIRCULATIONAHA.116.024611

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  44 in total

Review 1.  Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Authors:  Adam Taleb; Joseph L Witztum; Sotirios Tsimikas
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

2.  Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).

Authors:  Daniel Gaudet; Dean J Kereiakes; James M McKenney; Eli M Roth; Corinne Hanotin; Daniel Gipe; Yunling Du; Anne-Catherine Ferrand; Henry N Ginsberg; Evan A Stein
Journal:  Am J Cardiol       Date:  2014-06-18       Impact factor: 2.778

Review 3.  Lipoprotein(a): resurrected by genetics.

Authors:  F Kronenberg; G Utermann
Journal:  J Intern Med       Date:  2012-11-12       Impact factor: 8.989

4.  Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).

Authors:  Gregor Leibundgut; Corey Scipione; Huiyong Yin; Matthias Schneider; Michael B Boffa; Simone Green; Xiaohong Yang; Edward Dennis; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

5.  Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study.

Authors:  Rudy Guerra; Zhaoxia Yu; Santica Marcovina; Ronald Peshock; Jonathan C Cohen; Helen H Hobbs
Journal:  Circulation       Date:  2005-03-21       Impact factor: 29.690

6.  Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events.

Authors:  Sotirios Tsimikas; Ziad Mallat; Philippa J Talmud; John J P Kastelein; Nicholas J Wareham; Manjinder S Sandhu; Elizabeth R Miller; Joelle Benessiano; Alain Tedgui; Joseph L Witztum; Kay-Tee Khaw; S Matthijs Boekholdt
Journal:  J Am Coll Cardiol       Date:  2010-09-14       Impact factor: 24.094

7.  Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.

Authors:  Fangwen Rao; Andrew J Schork; Adam X Maihofer; Caroline M Nievergelt; Santica M Marcovina; Elizabeth R Miller; Joseph L Witztum; Daniel T O'Connor; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-05-07       Impact factor: 8.311

8.  Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Authors:  Sotirios Tsimikas; Nicholas J Viney; Steven G Hughes; Walter Singleton; Mark J Graham; Brenda F Baker; Jennifer L Burkey; Qingqing Yang; Santica M Marcovina; Richard S Geary; Rosanne M Crooke; Joseph L Witztum
Journal:  Lancet       Date:  2015-07-22       Impact factor: 79.321

9.  Apo[a] size and PNR explain African American-Caucasian differences in allele-specific apo[a] levels for small but not large apo[a].

Authors:  Jill Rubin; Han Jo Kim; Thomas A Pearson; Steve Holleran; Rajasekhar Ramakrishnan; Lars Berglund
Journal:  J Lipid Res       Date:  2006-02-22       Impact factor: 5.922

10.  A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.

Authors:  Majid Nikpay; Anuj Goel; Hong-Hee Won; Leanne M Hall; Christina Willenborg; Stavroula Kanoni; Danish Saleheen; Theodosios Kyriakou; Christopher P Nelson; Jemma C Hopewell; Thomas R Webb; Lingyao Zeng; Abbas Dehghan; Maris Alver; Sebastian M Armasu; Kirsi Auro; Andrew Bjonnes; Daniel I Chasman; Shufeng Chen; Ian Ford; Nora Franceschini; Christian Gieger; Christopher Grace; Stefan Gustafsson; Jie Huang; Shih-Jen Hwang; Yun Kyoung Kim; Marcus E Kleber; King Wai Lau; Xiangfeng Lu; Yingchang Lu; Leo-Pekka Lyytikäinen; Evelin Mihailov; Alanna C Morrison; Natalia Pervjakova; Liming Qu; Lynda M Rose; Elias Salfati; Richa Saxena; Markus Scholz; Albert V Smith; Emmi Tikkanen; Andre Uitterlinden; Xueli Yang; Weihua Zhang; Wei Zhao; Mariza de Andrade; Paul S de Vries; Natalie R van Zuydam; Sonia S Anand; Lars Bertram; Frank Beutner; George Dedoussis; Philippe Frossard; Dominique Gauguier; Alison H Goodall; Omri Gottesman; Marc Haber; Bok-Ghee Han; Jianfeng Huang; Shapour Jalilzadeh; Thorsten Kessler; Inke R König; Lars Lannfelt; Wolfgang Lieb; Lars Lind; Cecilia M Lindgren; Marja-Liisa Lokki; Patrik K Magnusson; Nadeem H Mallick; Narinder Mehra; Thomas Meitinger; Fazal-Ur-Rehman Memon; Andrew P Morris; Markku S Nieminen; Nancy L Pedersen; Annette Peters; Loukianos S Rallidis; Asif Rasheed; Maria Samuel; Svati H Shah; Juha Sinisalo; Kathleen E Stirrups; Stella Trompet; Laiyuan Wang; Khan S Zaman; Diego Ardissino; Eric Boerwinkle; Ingrid B Borecki; Erwin P Bottinger; Julie E Buring; John C Chambers; Rory Collins; L Adrienne Cupples; John Danesh; Ilja Demuth; Roberto Elosua; Stephen E Epstein; Tõnu Esko; Mary F Feitosa; Oscar H Franco; Maria Grazia Franzosi; Christopher B Granger; Dongfeng Gu; Vilmundur Gudnason; Alistair S Hall; Anders Hamsten; Tamara B Harris; Stanley L Hazen; Christian Hengstenberg; Albert Hofman; Erik Ingelsson; Carlos Iribarren; J Wouter Jukema; Pekka J Karhunen; Bong-Jo Kim; Jaspal S Kooner; Iftikhar J Kullo; Terho Lehtimäki; Ruth J F Loos; Olle Melander; Andres Metspalu; Winfried März; Colin N Palmer; Markus Perola; Thomas Quertermous; Daniel J Rader; Paul M Ridker; Samuli Ripatti; Robert Roberts; Veikko Salomaa; Dharambir K Sanghera; Stephen M Schwartz; Udo Seedorf; Alexandre F Stewart; David J Stott; Joachim Thiery; Pierre A Zalloua; Christopher J O'Donnell; Muredach P Reilly; Themistocles L Assimes; John R Thompson; Jeanette Erdmann; Robert Clarke; Hugh Watkins; Sekar Kathiresan; Ruth McPherson; Panos Deloukas; Heribert Schunkert; Nilesh J Samani; Martin Farrall
Journal:  Nat Genet       Date:  2015-09-07       Impact factor: 38.330

View more
  32 in total

Review 1.  Lp(a): Addressing a Target for Cardiovascular Disease Prevention.

Authors:  Nestor Vasquez; Parag H Joshi
Journal:  Curr Cardiol Rep       Date:  2019-07-31       Impact factor: 2.931

2.  A genome-wide association study on lipoprotein (a) levels and coronary artery disease severity in a Chinese population.

Authors:  Yibin Liu; Hongkun Ma; Qian Zhu; Bin Zhang; Hong Yan; Hanping Li; Jinxiu Meng; Weihua Lai; Liwen Li; Danqing Yu; Shilong Zhong
Journal:  J Lipid Res       Date:  2019-06-11       Impact factor: 5.922

Review 3.  Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?

Authors:  Željko Reiner
Journal:  Curr Atheroscler Rep       Date:  2019-03-07       Impact factor: 5.113

4.  Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options.

Authors:  Andreja Rehberger Likozar; Mark Zavrtanik; Miran Šebeštjen
Journal:  Ann Med       Date:  2020-06-08       Impact factor: 4.709

5.  Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort).

Authors:  Archna Bajaj; Scott M Damrauer; Amanda H Anderson; Dawei Xie; Matthew J Budoff; Alan S Go; Jiang He; James P Lash; Akinlolu Ojo; Wendy S Post; Mahboob Rahman; Muredach P Reilly; Danish Saleheen; Raymond R Townsend; Jinbo Chen; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-24       Impact factor: 8.311

Review 6.  NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.

Authors:  Sotirios Tsimikas; Sergio Fazio; Keith C Ferdinand; Henry N Ginsberg; Marlys L Koschinsky; Santica M Marcovina; Patrick M Moriarty; Daniel J Rader; Alan T Remaley; Gissette Reyes-Soffer; Raul D Santos; George Thanassoulis; Joseph L Witztum; Simhan Danthi; Michelle Olive; Lijuan Liu
Journal:  J Am Coll Cardiol       Date:  2018-01-16       Impact factor: 24.094

7.  Lipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans.

Authors:  Renata J M Engler; Emily Brede; Todd Villines; Marina N Vernalis
Journal:  Fed Pract       Date:  2019-11

8.  Lipoprotein(a) and Risk of Ischemic Stroke in the REGARDS Study.

Authors:  Pankaj Arora; Rajat Kalra; Peter W Callas; Kristine S Alexander; Neil A Zakai; Virginia Wadley; Garima Arora; Brett M Kissela; Suzanne E Judd; Mary Cushman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

9.  Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank.

Authors:  Aniruddh P Patel; Minxian Wang (汪敏先); James P Pirruccello; Patrick T Ellinor; Kenney Ng; Sekar Kathiresan; Amit V Khera
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-10-29       Impact factor: 8.311

10.  Association of Lipoprotein (a) variants with risk of cardiovascular disease: a Mendelian randomization study.

Authors:  Juan Xia; Chunyue Guo; Kuo Liu; Yunyi Xie; Han Cao; Wenjuan Peng; Yanyan Sun; Xiaohui Liu; Bingxiao Li; Ling Zhang
Journal:  Lipids Health Dis       Date:  2021-06-01       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.